Drug Type Synthetic peptide vaccine, Therapeutic vaccine |
Synonyms- |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fallopian Tube Carcinoma | Phase 2 | United States | 13 Apr 2006 | |
| Ovarian Cancer | Phase 2 | United States | 13 Apr 2006 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | United States | 13 Apr 2006 | |
| Melanoma, Cutaneous Malignant | Phase 2 | United States | 01 Mar 2005 | |
| Conjunctival Neoplasms | Phase 1 | United States | 01 May 2008 | |
| Uveal Melanoma | Phase 1 | United States | 01 May 2008 |
Phase 1/2 | 170 | multi-epitope melanoma peptide vaccine+tetanus toxoid helper peptide (Arm I) | xkgkqmzpds = oconbvhuwi kstswyysla (xsbypxkfld, mujpbtegfk - ohkfvxgjhn) View more | - | 20 Apr 2021 | ||
(Arm II) | xkgkqmzpds = dgqlelhfbf kstswyysla (xsbypxkfld, occeseexbh - yrnzteclov) View more |





